Page 160 - Simplicity is Key in CRT

160
27. Fein, A.S., et al., Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. J Am Coll Cardiol, 2010. 56(10): p. 766- 73.
28. Hess, P.L., et al., Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes? Heart Rhythm, 2013. 10(8): p. 1127-33.
29. Mehra, M.R., et al., Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. Heart Rhythm, 2009. 6(12): p. 1727-34.
30. Schneider, P.M., et al., Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchroniza- tion therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008. Am J Cardiol, 2014. 113(12): p. 2052-6.
31. Mullens, W., et al., Importance of adjunctive heart failure optimization immediately after implantation to improve long- term outcomes with cardiac resynchronization therapy. Am J Cardiol, 2011. 108(3): p. 409-15.
32. Verbrugge, F.H., et al., Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling. J Card Fail, 2012. 18(11): p. 845-53.
33. Panella, M., et al., Reduced in-hospital mortality for heart failure with clinical pathways: the results of a cluster randomised controlled trial. Qual Saf Health Care, 2009. 18(5): p. 369-73.
34. Kul, S., et al., Effects of care pathways on the in-hospital treatment of heart failure: a systematic review. BMC Cardiovasc Disord, 2012. 12: p. 81.
35. Mullens, W., et al., Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease manage- ment program. J Am Coll Cardiol, 2009. 53(9): p. 765-73.
36. Altman, R.K., et al., Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with im- proved clinical outcomes. Eur Heart J, 2012. 33(17): p. 2181-8.
37. Fonarow, G.C., et al., Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med, 2007. 167(14): p. 1493-502.
38. Fonarow, G.C., et al., Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation, 2010. 122(6): p. 585-96.
39. Singh,J.P.,etal.,Devicediagnosticsandlong-termclinicaloutcomeinpatientsreceivingcardiacresynchronizationthera- py. Europace, 2009. 11(12): p. 1647-53.
40. Whellan, D.J., et al., Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol, 2010. 55(17): p. 1803-10.
41. Cowie, M.R., The global relevance of disease management programmes for heart failure. Eur J Heart Fail, 2014. 16(9): p. 927-8.
42. Dubner, S., et al., ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace, 2012. 14(2): p. 278-93.
43. Wilkoff, B.L., et al., HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Europace, 2008. 10(6): p. 707-25.
44. Crossley, G., et al., Trial design of the clinical evaluation of remote notification to reduce time to clinical decision: the Clinical evaluation Of remote NotificatioN to rEduCe Time to clinical decision (CONNECT) study. Am Heart J, 2008. 156(5): p. 840-6.
45. Varma, N., et al., Efficacy and safety of automatic remote monitoring for implantable cardioverter- defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation, 2010. 122(4): p. 325-32.
46. Raatikainen, M.J., et al., Remote monitoring of implantable cardioverter defibrillator patients: a safe, time-saving, and cost-effective means for follow-up. Europace, 2008. 10(10): p. 1145-51.
47. Saxon, L.A., et al., Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTI- TUDE survival study. Circulation, 2010. 122(23): p. 2359-67.